Sponsor or institution

Clinical trials and research at Amgen

• 45Clinical trials
• 2New in 30 days
• 55Countries

Newest trials

All recruiting trials (45)

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• Home self-administration of a weight-management medicine with an autoinjector in adults who are overweight or obese

  This study tests whether adults who are overweight or have obesity can successfully self-administer maridebart cafraglutide at home using an autoinjector.

  Recruiting at 25 sites Phase 3 Amgen · San Diego, California and 24 other locations · NCT07871409

• Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin

  This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).

  Recruiting at 8 sites Phase 3 Amgen · San Diego, California and 7 other locations · NCT07866066

• Inebilizumab for primary membranous nephropathy in adults

  This study tests whether inebilizumab can help achieve complete remission in adults with primary membranous nephropathy who have significant protein in the urine.

  Recruiting at 4 sites Phase 3 Amgen · Los Angeles, California and 3 other locations · NCT07851220

• How the body absorbs romosozumab from one big shot vs two smaller injections

  This study tests whether a single large subcutaneous injection of romosozumab delivers the same amount of drug in the body as two smaller injections in healthy adults.

  Recruiting at 2 sites Phase 1 Amgen · Miami, Florida and 1 other locations · NCT07811999

• Tarlatamab given under the skin vs by IV in extensive-stage small cell lung cancer after platinum therapy

  This trial tests whether subcutaneous tarlatamab works as well as the IV form for people with extensive-stage small cell lung cancer after platinum chemotherapy.

  Recruiting at 9 sites Phase 3 Amgen · Orlando, Florida and 8 other locations · NCT07778316

• Romiplostim plus prednisone vs prednisone alone in adults with newly diagnosed ITP

  This phase 3 trial tests whether adding romiplostim to prednisone helps adults with newly diagnosed primary ITP respond better than prednisone alone.

  Recruiting at 3 sites Phase 3 Amgen · Long Beach, California and 2 other locations · NCT07700238

• Long-term test of maridebart cafraglutide in people who are overweight or have obesity

  This trial tests maridebart cafraglutide versus placebo to see if long-term treatment helps people who are overweight or obese manage weight safely and tolerably.

  Recruiting at 92 sites Phase 3 Amgen · Anniston, Alabama and 91 other locations · NCT07684235

• Long-term test of maridebart cafraglutide for obesity and type 2 diabetes

  This extension study tests whether maridebart cafraglutide remains effective and safe for people with obesity and type 2 diabetes who previously completed a parent trial.

  Recruiting at 45 sites Phase 3 Amgen · Gilbert, Arizona and 44 other locations · NCT07684144

• ABP 938 8 mg vs EYLEA® HD (aflibercept) in neovascular AMD

  This trial tests whether ABP 938 8 mg works as well as aflibercept 8 mg in people with neovascular AMD.

  Recruiting at 81 sites Phase 3 Amgen · Fullerton, California and 80 other locations · NCT07614776

• Inebilizumab for Autoimmune Hepatitis: a study in adults

  This trial tests whether inebilizumab can be safely used in adults with autoimmune hepatitis and whether it helps reduce liver disease activity and the need for steroids.

  Recruiting at 35 sites Phase 3 Amgen · Little Rock, Arkansas and 35 other locations · NCT07598825

• AMG 127 in healthy adults and adults with type 2 diabetes

  This study tests whether a single dose or multiple doses of AMG 127 are safe and tolerable in healthy adults and adults with type 2 diabetes.

  Recruiting at 2 sites Phase 1 Amgen · Lake Forest, California and 1 other locations · NCT07590193

• Switching GLP-1 RA to Maridebart Cafraglutide in Adults with Obesity or Overweight

  This study tests whether switching from a GLP-1 receptor agonist to maridebart cafraglutide is safe and tolerable for adults who are overweight or obese.

  Recruiting at 56 sites Phase 3 Amgen · Pelham, Alabama and 56 other locations · NCT07575399

• Tarlatamab plus ZL-1310, with or without durvalumab, for small cell lung cancer

  This trial will test whether combining tarlatamab with ZL-1310, with or without the PD-L1 drug durvalumab, is safe and tolerable for adults with small cell lung cancer who have received platinum chemotherapy or are newly diagnosed extensive-stage after one cycle of chemo.

  Recruiting at 27 sites Phase 1 Amgen · Goodyear, Arizona and 26 other locations · NCT07531095

• Xaluritamig in adults with metastatic castration-resistant prostate cancer

  A new drug called xaluritamig is being tested in adults with metastatic castration-resistant prostate cancer to see if it is safe with the planned dosing.

  Recruiting at 14 sites Phase 1 Amgen · Denver, Colorado and 13 other locations · NCT07493512

• AMG 732 for thyroid eye disease in a rollover, open-label study

  This study tests AMG 732 in adults with moderate-to-severe thyroid eye disease who previously did not respond or relapsed, to see if the treatment helps symptoms and is safe over a rollover period.

  Recruiting at 8 sites Phase 2 Amgen · Little Rock, Arkansas and 7 other locations · NCT07438405

• AMG 436 alone and with other treatments for adults with MSI‑High or dMMR advanced solid tumors

  This trial tests AMG 436 alone and combined with other cancer therapies in adults whose advanced solid tumors are MSI‑High (MSI‑H) or mismatch repair deficient (dMMR).

  Recruiting at 27 sites Phase 1 Amgen · Irvine, California and 26 other locations · NCT07403721

• Comparing subcutaneous versus intravenous pegloticase with methotrexate for uncontrolled gout

  This test compares subcutaneous pegloticase plus methotrexate to intravenous pegloticase plus methotrexate to see which better keeps uric acid under control in adults with uncontrolled gout.

  Recruiting at 75 sites Phase 3 Amgen · Birmingham, Alabama and 74 other locations · NCT07388498

• Pediatric safety follow-up after romosozumab treatment for osteogenesis imperfecta

  This follow-up tests the safety of romosozumab in children and adolescents with osteogenesis imperfecta who previously received romosozumab in an earlier trial.

  Recruiting at 4 sites Phase 3 Amgen · Indianapolis, Indiana and 3 other locations · NCT07366086

• Xaluritamig for relapsed or refractory Ewing sarcoma in adults, adolescents, and children

  This trial will test xaluritamig in adults, adolescents, and children with relapsed or refractory Ewing sarcoma to find a recommended dose for expansion and check safety and tolerability.

  Recruiting at 13 sites Phase 1 Amgen · Los Angeles, California and 12 other locations · NCT07297979

• Olpasiran to lower lipoprotein(a) and shrink non-calcified coronary plaque

  This trial will test whether olpasiran can lower very high Lp(a) and reduce non-calcified coronary plaque in adults 35–80 with prior heart attack or coronary revascularization.

  Recruiting at 40 sites Phase 3 Amgen · Bridgeport, Connecticut and 39 other locations · NCT07293260

• Xaluritamig plus abiraterone versus doctor's choice for chemo‑naïve metastatic castration‑resistant prostate cancer

  This phase 3 test checks whether adding xaluritamig to abiraterone helps men with chemotherapy‑naïve metastatic castration‑resistant prostate cancer live longer than standard doctor‑chosen options (docetaxel, cabazitaxel, or abiraterone alone).

  Recruiting at 154 sites Phase 3 Amgen · Goodyear, Arizona and 158 other locations · NCT07213674

• Continuing sotorasib with or without panitumumab for adults with KRAS p.G12C advanced solid tumors

  This trial tries continuing sotorasib, with or without panitumumab, in adults with KRAS p.G12C advanced solid tumors who are already benefiting from an Amgen trial to see if ongoing treatment remains safe and tolerable.

  Recruiting at 9 sites Phase 2 Amgen · Fort Myers, Florida and 10 other locations · NCT07172919

• Adding xaluritamig to androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer

  This trial tests whether adding xaluritamig to darolutamide or abiraterone is safe and tolerable for men with high-volume metastatic hormone-sensitive prostate cancer who have recently started hormone therapy.

  Recruiting at 16 sites Phase 1 Amgen · San Francisco, California and 15 other locations · NCT07140900

• Olpasiran to prevent a first major coronary event in people with high Lp(a)

  This trial tests whether olpasiran can lower the chance of a first heart attack, death from coronary heart disease, or urgent coronary revascularization in people age 50 and older with very high lipoprotein(a).

  Recruiting at 240 sites Phase 3 Amgen · Alexander City, Alabama and 251 other locations · NCT07136012

• AMG 410 alone and with other drugs for KRAS‑altered advanced or metastatic solid tumors

  This trial tests whether AMG 410, given alone or with pembrolizumab or panitumumab, is safe and shows anti‑tumor activity in adults with advanced or metastatic solid tumors that have KRAS alterations.

  Recruiting at 39 sites Phase 1 Amgen · Duarte, California and 38 other locations · NCT07094113

• Tarlatamab plus AB248 for extensive-stage small cell lung cancer (DeLLphi-311)

  This trial tests whether combining tarlatamab with AB248 is safe and tolerable for adults whose extensive-stage small cell lung cancer has progressed after prior therapy.

  Recruiting at 18 sites Phase 1 Amgen · Gilbert, Arizona and 18 other locations · NCT07037758

• Maridebart cafraglutide for people with obesity and preserved or mildly reduced ejection fraction heart failure

  This trial will test whether adding maridebart cafraglutide to usual heart-failure care can reduce hospital visits, cardiovascular deaths, and improve symptoms in adults with obesity and HFpEF or HFmrEF.

  Recruiting at 651 sites Phase 3 Amgen · Birmingham, Alabama and 685 other locations · NCT07037459

• Inebilizumab in children with generalized myasthenia gravis: drug handling and tolerability

  This trial will test inebilizumab in children aged 2 to 17 with generalized myasthenia gravis to see how the drug is processed in the body and whether it is safe and well tolerated.

  Recruiting at 14 sites Phase 2 Amgen · Chicago, Illinois and 13 other locations · NCT06987539

• Long-term evaluation of dazodalibep for Sjögren's Syndrome

  This study is testing how safe and well-tolerated the drug dazodalibep is for people with Sjögren's Syndrome who have already taken it in earlier trials.

  Recruiting at 174 sites Phase 3 Amgen · Avondale, Arizona and 173 other locations · NCT06747949

• Evaluating a new treatment for localized prostate cancer before surgery

  This study is testing a new treatment called xaluritamig to see if it can safely help men with localized prostate cancer before they have surgery.

  Recruiting at 9 sites Phase 1 Amgen · San Francisco, California and 8 other locations · NCT06613100

• Tarlatamab treatment for extensive stage small cell lung cancer

  This study is testing a new treatment called tarlatamab for people with extensive stage small cell lung cancer who haven't had success with previous chemotherapy to see if it helps them feel better.

  Recruiting at 31 sites Phase 1 Amgen · Los Angeles, California and 30 other locations · NCT06598306

• Testing inebilizumab and subcutaneous blinatumomab in adults with active, treatment‑resistant lupus or refractory rheumatoid arthritis

  This trial tests inebilizumab for adults with active, treatment‑resistant lupus with nephritis and tests subcutaneous blinatumomab for adults with active, treatment‑resistant lupus (with or without nephritis) and for adults with active refractory rheumatoid arthritis.

  Recruiting at 48 sites Phase 2 Amgen · Scottsdale, Arizona and 57 other locations · NCT06570798

• Comparing new treatments for metastatic colorectal cancer with a specific mutation

  This study is testing if a new combination of treatments can help people with a specific type of metastatic colorectal cancer feel better compared to standard treatments.

  Recruiting at 231 sites Phase 3 Amgen · Chandler, Arizona and 290 other locations · NCT06252649

• Registry to assess pregnancy outcomes in women with migraines using Aimovig

  This study is looking to see if using Aimovig during pregnancy affects the health of babies born to women with migraines compared to those who didn't use the medication.

  Recruiting Amgen · Durham, North Carolina · NCT06150781

• Evaluating Avacopan for ANCA-associated Vasculitis

  This study is testing if the medication avacopan is safe for people with ANCA-associated vasculitis who need strong treatments like cyclophosphamide or rituximab.

  Recruiting at 79 sites Phase 4 Amgen · Anchorage, Alaska and 82 other locations · NCT06072482

• Comparing two treatments for advanced lung cancer

  This study is testing whether a new drug called sotorasib with chemotherapy works better than pembrolizumab with chemotherapy for people with advanced lung cancer that has a specific KRAS mutation.

  Recruiting at 312 sites Phase 3 Amgen · Santa Barbara, California and 417 other locations · NCT05920356

• Monitoring the safety of UPLIZNA in pregnant women with NMOSD

  This study is trying to see how safe the medication UPLIZNA is for pregnant women with Neuromyelitis Optica Spectrum Disorder (NMOSD) by tracking their pregnancies and outcomes over the next 10 years.

  Recruiting Amgen · Aurora, Colorado · NCT05909761

• Using Apremilast to treat oral ulcers in children with Behçet's disease or juvenile psoriatic arthritis

  This study is testing if the medication apremilast can safely help children with oral ulcers from Behçet's disease or juvenile psoriatic arthritis feel better over a longer time.

  Recruiting at 7 sites Phase 3 Amgen · Thessaloniki and 6 other locations · NCT05767047

• Evaluating Inebilizumab for Children with Neuromyelitis Optica Spectrum Disorder

  This study is testing a new treatment called inebilizumab to see if it can help children with a specific type of neuromyelitis optica spectrum disorder feel better and stay safe during the treatment.

  Recruiting at 19 sites Phase 2 Amgen · La Jolla, California and 18 other locations · NCT05549258

• Treatment of active juvenile psoriatic arthritis in children using apremilast

  This study is testing if a medication called apremilast can help children with active juvenile psoriatic arthritis feel better compared to a placebo.

  Recruiting at 23 sites Phase 3 Amgen · Ghent and 43 other locations · NCT04804553

• Treatment of oral ulcers in children with Behçet's disease using apremilast

  This study is testing if a medication called apremilast can help children with Behçet's disease feel better by reducing their painful mouth sores.

  Recruiting at 20 sites Phase 3 Amgen · Bron and 26 other locations · NCT04528082

• Evaluating AMG 509 for advanced prostate cancer

  This study is testing a new drug called AMG 509 to see if it can be safely used with other treatments for adults with advanced prostate cancer who haven't had success with other therapies.

  Recruiting at 53 sites Phase 1 Amgen · Duarte, California and 56 other locations · NCT04221542

• Treatment of secondary hyperparathyroidism in children on hemodialysis

  This study tests if a new medication called etelcalcetide can help children on hemodialysis lower their parathyroid hormone levels safely.

  Recruiting at 10 sites Phase 3 Amgen · Ghent and 22 other locations · NCT03969329

• Etelcalcetide treatment for children with kidney disease and high parathyroid hormone levels

  This study is testing if a new treatment called Etelcalcetide can help children with kidney disease and high parathyroid hormone levels feel better and avoid serious health problems.

  Recruiting at 19 sites Phase 3 Amgen · Los Angeles, California and 42 other locations · NCT03633708

Quick answers

How many clinical trials run by Amgen are recruiting right now?

45, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 55 countries. The most sites are in United States (38 trials), Spain (20 trials), Australia (19 trials), France (17 trials), Germany (17 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 24, Phase 1: 13, Phase 2: 5, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →